引用本文:王新亭,张传雷,陈晓琦,冀爱英,陈欣菊,袁 媛.牛磺熊去氧胆酸治疗重度黄疸型乙型病毒性肝炎的疗效观察[J].中国临床新医学,2018,11(12):1243-1245.
【打印本页】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 47次   下载 26 本文二维码信息
码上扫一扫!
分享到: 微信 更多
牛磺熊去氧胆酸治疗重度黄疸型乙型病毒性肝炎的疗效观察
王新亭,张传雷,陈晓琦,冀爱英,陈欣菊,袁 媛
450000 郑州,河南中医药大学第一附属医院消化内科
摘要:
[摘要] 目的 探讨牛磺熊去氧胆酸治疗重度黄疸型乙型病毒性肝炎的疗效。方法 将80例重度黄疸型乙型病毒性肝炎患者随机分为干预组和对照组,每组40例。对照组给予恩替卡韦抗病毒及还原型谷胱甘肽、复方甘草酸苷保肝类药物常规治疗。干预组在常规治疗的基础上,给予牛磺熊去氧胆酸胶囊250 mg口服,2次/d。时间均为14 d。观察两组患者治疗前后总胆红素(TBIL)、直接胆红素(DBIL)、谷丙转氨酶(ALT)、谷草转氨酶(AST)及碱性磷酸酶(ALP)变化情况。结果 两组患者的TBIL、DBIL、ALT、AST、ALP水平治疗后较治疗前均明显下降,差异有统计学意义(P<0.05);干预组较对照组降低更明显,差异有统计学意义(P<0.05)。应用牛磺熊去氧胆酸患者仅1例出现轻微上腹部不适症状。结论 牛磺熊去氧胆酸辅助治疗重度黄疸型乙型病毒性肝炎可明显降低TBIL、DBIL、ALT、AST及ALP水平。
关键词:  乙型病毒性肝炎  牛磺熊去氧胆酸  临床观察
DOI:10.3969/j.issn.1674-3806.2018.12.19
分类号:R 512.6
基金项目:
Efficacy of tauroursodeoxycholic acid in treatment of severe jaundice type B viral hepatitis
WANG Xin-ting, ZHANG Chuan-lei, CHEN Xiao-qi, et al.
Department of Gastroenterology, the First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou 450000, China
Abstract:
[Abstract] Objective To investigate the efficacy of tauroursodeoxycholic acid in treatment of severe jaundice type B viral hepatitis. Methods Eighty patients with severe jaundice type B viral hepatitis were randomly divided into intervention group and control group, with 40 cases in each group. The control group was given entecavir anti virus, and then treated with glutathione and compound glycyrrhizin. On the basis of routine treatment, the intervention group was given tauroursodeoxycholic acid capsules 250 mg orally, 2 times daily for 14 days. The changes of total bilirubin(TBIL), direct bilirubin(DBIL), alanine aminotransferase(ALT), aspartate aminotransferase(AST) and alkaline phosphatase(ALP) were observed in the two groups before and after treatment. Results In the two groups, compared with those before treatment, the levels of TBIL, DBIL, ALT, AST and ALP were significantly decreased after treatment(P<0.05), while those in the intervention group were decreased more significantly than those in the control group(P<0.05). Only one patient receiving tauroursodeoxycholic acid had mild symptoms of upper abdominal discomfort. Conclusion As an adjuvant therapy, tauroursodeoxycholic acid can significantly reduce the total bilirubin(TBIL) and direct bilirubin(DBIL), alanine aminotransferase(ALT) and aspartate aminotransferase(AST) and alkaline phosphatase(ALP) for the patients with severe jaundice type B viral hepatitis.
Key words:  Hepatitis B  Tauroursodeoxycholic acid  Clinical observation